
TenNor Therap-B
06872 · HKEXDano Pharmaceutical is a biotechnology company approaching the commercialization stage, focusing on the discovery, development and commercialization of differentiated innovative pharmaceutical product…
Calendrier de l'IPO
- OuvrirMay 14
- FermerMay 19
- Montant allouéMay 21
- PaiementMay 22
- ListeMay 22
Principaux faits
Prix d'émission
HKD 75.70
Frais d'entrée dans les mines
HKD 3,823.17
Actions émises
8.86M
Taille du lot
50
Augmentation totale
HKD 670.4M
Montant estimatif du plafond du marché
HKD 3.92B
Allocation publique
10.0%
Placement international
90.0%
Aperçu des activités
Dano Pharmaceutical is a biotechnology company approaching the commercialization stage, focusing on the discovery, development and commercialization of differentiated innovative pharmaceutical products to address unmet clinical needs in the fields of bacterial infections and bacterial metabolism‑related diseases.
Utilisation des produits
1、71.0% or approximately HK$395.7 million will be used for the research, development, registration filing and commercialisation of the Company’s core products;
2、7.0% or approximately HK$39.2 million will be used to fund the research and development of the oral formulation of TNP‑2092;
3、7.3% or approximately HK$40.9 million will be used for the research and development of other candidate products of the Company;
4、7.2% or approximately HK$40.2 million will be used for the construction of the Company’s own manufacturing plant;
5、7.5% or approximately HK$41.8 million will be used as working capital and for other general corporate purposes.
Dossier de suivi du promoteur
Intermédiaires et documents
Parrains
- 中信證券(香港)有限公司
- 農銀國際融資有限公司
Sous-traitants
- 中信里昂證券有限公司
- 農銀國際證券有限公司
- 華興證券(香港)有限公司
- 富途證券國際(香港)有限公司
- 老虎證券(香港)環球有限公司
Prospectus PDF
Prospectus PDF →Investisseurs de pierres angulaires
- AMR Action Fund, L.P.
- 华圆管理咨询(香港)有限公司
- AMR Action Fund, SCSp
- 东方资产管理(香港)有限公司
- 骏升环球有限公司
Total
0
37.3% of placement
BBX ne participe pas au processus d'attribution d'un OPI énuméré sur cette page. Cette page n'est qu'à titre informatif et n'est pas un conseil en investissement.